Exhibit 4.7
This Amendment Two is effective from 22 February 2024
BETWEEN:
(1) CELL THERAPY CATAPULT LIMITED, trading as Cell and Gene Therapy Catapult, incorporated and registered in England and Wales with company number 07964711 whose registered office is at 12th Floor Tower Wing, Guys Hospital, Great Maze Pond, London, SE1 9RT (“Catapult”); and
(2) ACHILLES THERAPEUTICS UK LIMITED, a company incorporated in England and Wales with company number 10167668 whose registered office is at 245 Hammersmith Road, London, United Kingdom, W6 8PW (“Achilles”),
each a “Party” and together the “Parties”.
BACKGROUND
(A) The Parties entered into a collaboration agreement dated 28th February 2020 in respect of Achilles’ occupation of a module at Catapult’s Manufacturing Centre located at Gunnels Wood Road, Stevenage SG1 2FX Stevenage, which was amended by agreement on 12 December 2022 (the “Agreement”).
(B) The Parties are entering into this amendment to effect an extension to the term of the Agreement from 28 February 2024 to 31 March 2025.
(C) The Parties hereby agree to amend the Agreement as set out in this Amendment Two.
IT IS AGREED AS FOLLOWS:
“This Agreement, and the licences granted hereunder, will come into effect on the Effective Date and, unless terminated earlier in accordance with this Clause 17 or unless specified in the continuing obligations provisions of this Agreement as having continued effect, will continue in force until 31 March 2025 (the “Term”), and on such date this Agreement will terminate automatically by expiry.”
IN WITNESS WHEREOF this Amendment Two is executed as follows:
For and on behalf of CELL THERAPY CATAPULT LIMITED:
| For and on behalf of ACHILLES THERAPEUTICS UK LIMITED | ||
Signed: | /s/ Matthew Durdy
| Signed: | /s/ Iraj Ali
|
Print Name: | Matthew Durdy
| Print Name: | Iraj Ali
|
Job Title: | Chief Executive Officer
| Job Title: | CEO
|
Date: | 22-Feb-2024 | 09:29 GMT
| Date: | 22-Feb-2024 | 09:39 GMT
|
2